Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1651 1653 1656
This examiner grants 58% of resolved cases
Paul J. Holland is an examiner in Tech Center 1600 and Art Unit 1636. He has 779 resolved cases. The allowance rate is 57.4 percent. The interview lift is 64.8 percent. This 64.8 percent lift is exceptionally high and suggests that interviews are a critical tool for success. The 64.8 percent lift is actually higher than the 57.4 percent allowance rate itself. This indicates that an interview significantly changes the probability of allowance for a given case.
The median days to allowance is 1094. This 1094-day timeline represents the typical pendency for applications under his review. Practitioners should prepare for a 1094-day process. The 779 resolved cases provide a solid statistical basis for these conclusions. Given the 57.4 percent allowance rate, the 64.8 percent lift is a vital factor for practitioners to leverage. The 1094-day median is a consistent measure of timing in Art Unit 1636. These 779 cases reflect a significant body of work for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17965366 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Non-Final OA | Intellia Therapeutics, Inc. |
| 17826545 | CELL CULTURE METHOD, ANTIBODY PRODUCTION METHOD, ORGANIC ACID REMOVAL METHOD, AND ANTIBODY | Final Rejection | FUJIFILM Corporation |
| 17820488 | RETINAL ORGANOID MODEL SYSTEMS | Final Rejection | Wisconsin Alumni Research Foundation |
| 18278695 | METHODS FOR GENERATING A CRISPR ARRAY | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17997877 | ACE2 COMPOSITIONS AND METHODS | Final Rejection | The Regents of the University of California |
| 19368582 | ENGINEERED PROTEINS AND METHODS OF USE THEREOF | Final Rejection | Pairwise Plants Services, Inc. |
| 18175893 | ENGINEERED PROTEINS AND METHODS OF USE THEREOF | Non-Final OA | Pairwise Plants Services, Inc. |
| 18143492 | Modulation of Gene Expression Via Transcription Factor-Chemically Induced Proximity (TF-CIP) | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18548640 | REDUCING HIGH MANNOSE GLYCAN PROTEIN EXPRESSION USING GUANOSINE 5'-MONOPHOSPHATE | Final Rejection | MERCK SHARP & DOHME LLC |
| 18021135 | CELL HAVING GENE CORRECTED EX VIVO AND USE THEREOF | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 17921035 | CHIMERIC POLYPEPTIDES AND METHODS OF PREPARING SAME | Final Rejection | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 17525433 | CELL ENGINEERING USING RNAs | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18691573 | FACILITATED DELIVERY OF CONCENTRATED ANTIBODY FORMULATIONS USING HYALURONIDASE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18434301 | DELIVERY OF ACTIVE AGENTS | Non-Final OA | MannKind Corporation |
| 18816810 | CLASS II, TYPE V CRISPR SYSTEMS | Non-Final OA | METAGENOMI, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy